Supplementary Material for:

Cancer Cell Profiling by Barcoding Allows Multiplexed Protein Analysis in Fine-Needle Aspirates

Adeeti V. Ullal, Vanessa Peterson, Sarit S. Agasti, Suan Tuang, Dejan Juric, Cesar M. Castro, Ralph Weissleder*

*Corresponding author. E-mail: rweissleder@mgh.harvard.edu

Published 15 January 2014, Sci. Transl. Med.6, 219ra9 (2014)
DOI: 10.1126/scitranslmed.3007361

This PDF file includes:

• Methods
• Fig. S1. Scheme of DNA-antibody conjugation.
• Fig. S2. Optimizing lysis and blocking methods.
• Fig. S3. DNA per antibody for each conjugate.
• Fig. S4. Effect of permeabilization schemes on antibody labeling.
• Fig. S5. Comparison of unmodified antibodies to DNA-antibody conjugates.
• Fig. S6. Validation of DNA-antibody conjugates.
• Fig. S7. Protein marker expression correlates with flow cytometry.
• Fig. S8. Single-cell variability in treated and untreated A431 cells.
• Fig. S9. Protein marker changes correlate with drug sensitivity.
• Fig. S10. Taxol treatment and dose-response screen in human HT1080 cells in vitro.
• Table S1. List of antibodies.
• Table S2. Significant markers between A431 single cells with or without gefitinib.
• Table S3. Differential markers between responders and nonresponders.
• Table S4. List of 70-mer alien sequences used for barcoding.

[Download PDF]